CCS
ONCE

Crosspoint Capital Strategies’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Crosspoint Capital Strategies’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-43,333
Closed -$3.86M – 141
2017
Q3 		$3.86M Buy
+43,333
New +$3.29M 2.99% 18

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Crosspoint Capital Strategies's ONCE Position: Q4 2017 in Review

Crosspoint Capital Strategies sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2017, closing a stake of 43,333 shares — an estimated $3.86M sold.

Crosspoint Capital Strategies first reported a position in ONCE in Q3 2017 and held it in 1 quarter. The position peaked at $3.86M in Q3 2017. 160 funds tracked by Wall St. Rank hold ONCE as of Q4 2017.

  • Crosspoint Capital Strategies reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 43,333 Spark Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $3.86M.
  • Crosspoint Capital Strategies first reported a position in Spark Therapeutics, Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • Crosspoint Capital Strategies's Spark Therapeutics, Inc. Common Stock position peaked at $3.86M in Q3 2017.
  • 160 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Crosspoint Capital Strategies's 13F filing for Q4 2017, filed 13 Feb 2018.